342 related articles for article (PubMed ID: 25202307)
1. Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches.
Joshi S; Rawat K; Yadav NK; Kumar V; Siddiqi MI; Dube A
Front Immunol; 2014; 5():380. PubMed ID: 25202307
[TBL] [Abstract][Full Text] [Related]
2. Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis.
Kumari P; Mamud A; Jha AN
Curr Drug Targets; 2023; 24(13):1023-1031. PubMed ID: 37823567
[TBL] [Abstract][Full Text] [Related]
3. The potential impact of human visceral leishmaniasis vaccines on population incidence.
Le Rutte EA; Coffeng LE; Malvolti S; Kaye PM; de Vlas SJ
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008468. PubMed ID: 32614857
[TBL] [Abstract][Full Text] [Related]
4. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
5. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
[TBL] [Abstract][Full Text] [Related]
6. The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?
Muniaraj M
Trop Parasitol; 2014 Jan; 4(1):10-9. PubMed ID: 24754021
[TBL] [Abstract][Full Text] [Related]
7. In silico designing of a novel polyvalent multi-subunit peptide vaccine leveraging cross-immunity against human visceral and cutaneous leishmaniasis: an immunoinformatics-based approach.
Bhattacharjee M; Banerjee M; Mukherjee A
J Mol Model; 2023 Mar; 29(4):99. PubMed ID: 36928431
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models.
Le Rutte EA; Coffeng LE; Bontje DM; Hasker EC; Postigo JA; Argaw D; Boelaert MC; De Vlas SJ
Parasit Vectors; 2016 Jan; 9():24. PubMed ID: 26787302
[TBL] [Abstract][Full Text] [Related]
9. Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.
Das VNR; Siddiqui NA; Bhunia GS; Pandey K; Sinha SK; Ansari MZ; Topno RK; Lal CS; Ranjan A; Singh VP; Das P
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009598. PubMed ID: 34428232
[TBL] [Abstract][Full Text] [Related]
10. Barriers to the effective management and prevention of post kala-azar dermal leishmaniasis (PKDL) in the Indian subcontinent.
Pal B; Kumari S; Kaur M; Wadhwa P; Murti K; Kumar R; Pandey K; Siddiqui NA; Dhingra S; Padmakar S
Med J Armed Forces India; 2023; 79(5):500-505. PubMed ID: 37719909
[TBL] [Abstract][Full Text] [Related]
11. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.
Kumar A; Samant M
Parasite Immunol; 2016 May; 38(5):273-81. PubMed ID: 27009772
[TBL] [Abstract][Full Text] [Related]
13. Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse.
Mondal D; Ghosh P; Chowdhury R; Halleux C; Ruiz-Postigo JA; Alim A; Hossain F; Khan MAA; Nath R; Duthie MS; Kroeger A; Matlashewski G; Argaw D; Olliaro P
Front Microbiol; 2019; 10():2268. PubMed ID: 31649631
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
Singh S ; Kumar J; Singh R; Dwivedi SN
Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183
[TBL] [Abstract][Full Text] [Related]
15. Possibilities and challenges for developing a successful vaccine for leishmaniasis.
Srivastava S; Shankar P; Mishra J; Singh S
Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732
[TBL] [Abstract][Full Text] [Related]
16. Cloning, expression and in vitro validation of chimeric multi epitope vaccine candidate against visceral leishmaniasis infection.
Ojha R; Chand K; Vellingiri B; Prajapati VK
Life Sci; 2023 Jun; 323():121689. PubMed ID: 37044174
[TBL] [Abstract][Full Text] [Related]
17. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
Duarte MC; Lage DP; Martins VT; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Goulart LR; Soto M; Tavares CA; Coelho EA
Rev Soc Bras Med Trop; 2016; 49(4):398-407. PubMed ID: 27598624
[TBL] [Abstract][Full Text] [Related]
18. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
19. Inferring transmission trees to guide targeting of interventions against visceral leishmaniasis and post-kala-azar dermal leishmaniasis.
Chapman LAC; Spencer SEF; Pollington TM; Jewell CP; Mondal D; Alvar J; Hollingsworth TD; Cameron MM; Bern C; Medley GF
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25742-25750. PubMed ID: 32973088
[TBL] [Abstract][Full Text] [Related]
20. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A; Singh VK; Tiwari R; Madhukar P; Rajneesh ; Kumar S; Gautam V; Engwerda C; Sundar S; Kumar R
Front Immunol; 2023; 14():1236952. PubMed ID: 37638047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
